Immunologic Response to Hepatitis B Virus Vaccination among Human Immunodeficiency Virus Thai Adults without Hepatitis B Virus Infection

2021 ◽  
Vol 104 (11) ◽  
pp. 1828-1835
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Hepatitis B Vaccination ◽  
Immunization Program ◽  
Hbv Vaccine ◽  
Negative Results ◽  
Hbv Vaccination ◽  
Younger Age ◽  
B Virus ◽  
Immunodeficiency Virus

Background: It is currently recommended that hepatitis B virus (HBV) vaccine be provided for every HIV-infected patient with no HBV immunity. HBV immunization program for HIV-infected patients was suggested to be given in three doses of vaccine at zero, one and six months. HBV vaccine has been included in the Thai immunization program for newborns for three doses, at birth, M2, and M6. Hence, one dose of vaccination might respond in complete protective immunity in some of the HIV patients. Objective: To evaluate HIV-infected patients’ response to one dose of vaccine and their associated factors. Materials and Methods: The present study was a Retrospective Cohort Study. It recruited patients who had come to Queen Savang Vadhana Memorial Hospital for their hepatitis B vaccination between January 1, 2018 and March 31, 2020. Eligible patients were infected with HIV, received ART, and had CD4 of more than 200 cells/mm³. The authors collected data from the patients having anti-HBs of less than 10 mIU/mL with negative anti-HBc who received HBV vaccine. From the medical records, the authors evaluated their anti-HBs titer after the first dose of vaccination, and the titer after a third dose, in cases the result of the first dose was negative. Results: Of the 88 HIV-infected patients who received HBV vaccination, 19 patients (21.6%) showed protective anti-HBs after the first dose of vaccination. Factors associated with the presence of anti-HBs after the first dose included age as the patients of 29 years or older had protective anti-HBs of 15% and the patients younger than 29 years old had protective anti-HBs of 43% (p=0.013), and anti-HBs titer before the vaccination as the patients with titer of less than 2 mIU/mL had protective anti-HBs of 17% and the patients with titer of 2 to less than 10 mIU/mL had protective anti-HBs of 44% (p=0.038). Conclusion: Some HIV-infected patients have developed protective anti-HBs after the first dose of HBV vaccination especially the younger age of less than 29 years old and with an anti-HBs titer before vaccination of 2 mlU/mL or above. Almost half of them required only one HBV booster to achieve protective anti-HBs. Keywords: Vaccine; Hepatitis B; HIV; Vaccination; Immunity

scholarly journals Prevalence of hepatitis B virus infection and carriage after nineteen years of vaccination program in the Western Brazilian Amazon

2012 ◽  
Vol 45 (1) ◽  
pp. 13-17 ◽  
Author(s):  
Wornei Silva Miranda Braga ◽  
Márcia da Costa Castilho ◽  
Fabiane Giovanella Borges ◽  
Ana Cristina de Souza Martinho ◽  
Ivo Seixas Rodrigues ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Brazilian Amazon ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Public Health Issue ◽  
Clinical Aspects ◽  
Inverse Association ◽  
Hbv Vaccination ◽  
B Virus

INTRODUCTION: Reductions in the prevalence of hepatitis B virus (HBV) infection and carriage, decreases in liver cancer incidence, and changes in patterns of liver dysfunctions are described after hepatitis B vaccination. METHODS: We conducted a population-based seroprevalence study aimed at estimating the HBV prevalence and risk of infection in the rural area of Lábrea following nineteen years of HBV vaccination. RESULTS: Half of the subjects showed total anti-HBc of 52.1% (95% CI 49.6-54.7). The HBsAg prevalence was 6.2% (95% CI 5.1-7.6). Multivariate analysis showed an inverse association between HBV infection and vaccination (OR 0.62; 95% CI 0.44-0.87). HBsAg remained independently associated with past hepatitis (OR 2.44; 95% CI 1.52-3.89) and inversely to vaccination (OR 0.43; 95% CI 0.27-0.69). The prevalence of HBeAg among HBsAg-positive individuals was 20.4% (95% CI 12.8-30.1), with the positive subjects having a median age of 11 years (1-46) p=0.0003. CONCLUSIONS: We demonstrate that HBV infection is still an important public health issue and that HBV vaccination could have had better impact on HBV epidemiology. If we extrapolate these findings to other rural areas in the Brazilian Amazon, we can predict that the sources of chronic infected patients remain a challenge. Future studies are needed regarding clinical aspects, molecular epidemiology, surveillance of acute cases, and risk groups.

scholarly journals Effect of Revaccination Using Different Schemes among Adults with Low or Undetectable Anti-HBs Titers after Hepatitis B Virus Vaccination

2010 ◽  
Vol 17 (10) ◽  
pp. 1548-1551 ◽  
Author(s):  
Chao-Shuang Lin ◽  
Shi-Bin Xie ◽  
Jing Liu ◽  
Zhi-Xin Zhao ◽  
Yu-Tian Chong ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Geometric Mean ◽  
Recombinant Vaccine ◽  
Recombinant Hepatitis ◽  
Healthy Male ◽  
Hbv Vaccine ◽  
Hbv Vaccination ◽  
Conversion Rates ◽  
B Virus

ABSTRACT Our objective was to investigate the effect of various reimmunization schemes for hepatitis B in adults with low or undetectable anti-HBs titers. Over 2 years, 10 μg of Saccharomyces cerevisiae-recombinant hepatitis B virus (HBV) vaccine (synthesized in China) was used in at least one standardized scheme to immunize 2,310 healthy male and nonpregnant female adults. Of these, 240 subjects tested negative for hepatitis B markers. These 240 subjects were equally divided into 4 groups. The first group, designated Engerix-40, was revaccinated with 40 μg Engerix-B; the second, Engerix-20, was revaccinated with 20 μg Engerix-B; the third, Chinese-20, was revaccinated with 20 μg Chinese-made yeast-recombinant vaccine; and the last group, Chinese-10, was revaccinated with 10 μg Chinese-made yeast-recombinant vaccine. Blood samples were collected before and 1, 2, 8, and 12 months after the first injection. The anti-HBs-positive conversion rates of the Engerix-40, Engerix-20, and Chinese-20 groups were higher than that of the Chinese-10 group (P < 0.01). Over time, the anti-HBs conversion rate increased in all groups, but values were significantly different from those for the other groups only in the Chinese-10 group (P < 0.001). The anti-HBs geometric mean titers (GMTs) of the Engerix-40, Engerix-20, and Chinese-20 groups were higher than in the Chinese-10 group (P < 0.05). Increased doses raise and maintain anti-HBs titers in subjects with low or undetectable titers after HBV vaccination.

scholarly journals Awareness of Hepatitis B Vaccination in Rural Area: A Survey

2014 ◽  
Vol 1 (1) ◽  
pp. 3-7
Author(s):  
Kamrun Nahar Sweety ◽  
Shamim Akther Mimi
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Rural Area ◽  
Cross Sectional Study ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Cross Sectional ◽  
Hbv Vaccination ◽  
B Virus ◽  
Almost All

Background: The awareness regarding Hepatitis B vaccination is necessary in the general population of Bangladesh.Objective: This study was carried out to determine the level of knowledge and the vaccination coverage of hepatitis B virus in rural population.Methodology: This cross sectional study was conducted at Bangladesh Institute of Administration and Management (BIAM), Dhaka, Bangladesh from February 2011 to April 2011. Sirajdikhan upazila of Munshiganj District was taken as a study place. All the villagers with an age group of 15 to 55 years were taken as study population. Result: A total number of 30 respondents were recruited of which male (60.0%) is predominant than female (40.0%). The mean age with SD was 23±7.256 years (range 15-53 years). Majority has told about the knowledge regarding the sequel of hepatitis B virus infection (33.3%). Almost all respondents (96.7%) are unknown about the treatment of HBV infection. Majority (76.7%) are unknown regarding taking HBV vaccination. Nobody has given positive answer in response to take vaccine. Conclusion: In conclusion information and knowledge regarding HBV infection and vaccination is very poor in the rural area of Bangladesh.DOI: http://dx.doi.org/10.3329/jcamr.v1i1.19558J Curr Adv Med Res 2014;1(1):3-7

scholarly journals The long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in Italy

2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Nicola Coppola ◽  
Anna Rita Corvino ◽  
Stefania De Pascalis ◽  
Giuseppe Signoriello ◽  
Eliana Di Fiore ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Recombinant Hepatitis ◽  
Hbv Vaccine ◽  
Hbv Vaccination ◽  
B Virus

Changes in the intrafamilial transmission of hepatitis B virus after introduction of a hepatitis B vaccination programme in Korea

2009 ◽  
Vol 138 (8) ◽  
pp. 1090-1095 ◽  
Author(s):  
S. H. JEONG ◽  
H. W. YIM ◽  
S. H. YOON ◽  
Y. M. JEE ◽  
S. H. BAE ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Vaccination Programme ◽  
Hepatitis B Vaccination ◽  
Birth Cohorts ◽  
Sampling Weights ◽  
Intrafamilial Transmission ◽  
Hbsag Positivity ◽  
Hbv Vaccination ◽  
B Virus

SUMMARYHepatitis B virus (HBV) infections are endemic in Korea. The aims of this study were to determine the prevalence of HBsAg positivity in Korea and to evaluate the changes in intrafamilial transmission after introduction of HBV vaccination in 1983. This study was based on the 2001 Korea National Health and Nutrition Examination Survey. A total of 2512 study subjects, aged 10–29 years, were selected from across Korea using a stratified multi-stage probability sampling design. To identify the changes in intrafamilial transmission after the introduction of the HBV vaccination programme, 1850 subjects with parental serological markers were selected. These subjects were then grouped into two birth cohorts (cohort 1: born before 1983; cohort 2: born after 1983). Appropriate sampling weights were used for all analyses. The weighted age-specific prevalence of HBsAg was 4·9% in participants in their 20s and 1·9% in adolescents; the combined weighted prevalence was 3·2%. Of subjects with HBsAg positivity in either parent, 17·5% were HBsAg-seropositive. Of subjects with two HBsAg-negative parents, 1·5% were HBsAg-seropositive. The HBsAg positivity rate of offspring with HBsAg-positive mothers was higher than those with HBsAg-positive fathers (27·3% vs. 4·8%, P<0·001). The weighted HBsAg positivity rate of offspring with HBsAg-negative mothers was 2·3% for cohort 1 and 0·4% for cohort 2 (P<0·01), and for those offspring with HBsAg-positive mothers it was also significantly decreased compared to cohorts 1 and 2 (40·2% vs. 16·4%, P<0·01). However, the weighted HBsAg positivity rate of offspring with HBsAg-positive mothers was still high. Our results showed that introduction of HBV vaccination has resulted in a decline in the overall HBsAg positivity rate and a reduction in intrafamilial transmission in Korea, but further preventive measures for maternal intrafamilial transmission are needed.

scholarly journals The Number of Infants with Hepatitis B virus (HBV) added Each Day in India

2021 ◽  
Vol 33 (1) ◽  
pp. 234-235
Author(s):  
Umesh Kapil
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Close Contact ◽  
Global Public Health ◽  
Immunization Program ◽  
Universal Immunization Program ◽  
Hbv Vaccination ◽  
B Virus ◽  
Chronic Hbv ◽  
To Receive

Hepatitis B virus (HBV) is one of the major global public health problems.HBV infection is the 10th leading cause of death.(1) In India, HBsAg prevalence,(an indicator of chronic HBV infection) among general population ranges from 2% to 8%.(2) HBV vaccination has been integrated in the Universal Immunization Program (UIP) for last 10 years. All new borns are expected to receive HBV vaccination at 0 day and subsequently at 6, 10 and 14 weeks. Majority of women do not know they are HBV infected. Often they do not have no symptoms. When a pregnant woman has hepatitis B, it can spread to her baby at birth. This can happen during a vaginal delivery or a c-section. Babies and young children can also get hepatitis B from close contact with family members or others who might be infected. When babies become infected with hepatitis B, they have about a 90% chance of developing a lifelong, chronic infection.

scholarly journals Strategies to Inhibit Hepatitis B Virus at the Transcript Level

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1327
Author(s):  
Bingqian Qu ◽  
Richard J. P. Brown
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Gene Transcription ◽  
Antigen Expression ◽  
Transcript Level ◽  
Viral Gene ◽  
Small Interfering Rnas ◽  
Viral Gene Transcription ◽  
Hbv Vaccination ◽  
B Virus

Approximately 240 million people are chronically infected with hepatitis B virus (HBV), despite four decades of effective HBV vaccination. During chronic infection, HBV forms two distinct templates responsible for viral transcription: (1) episomal covalently closed circular (ccc)DNA and (2) host genome-integrated viral templates. Multiple ubiquitous and liver-specific transcription factors are recruited onto these templates and modulate viral gene transcription. This review details the latest developments in antivirals that inhibit HBV gene transcription or destabilize viral transcripts. Notably, nuclear receptor agonists exhibit potent inhibition of viral gene transcription from cccDNA. Small molecule inhibitors repress HBV X protein-mediated transcription from cccDNA, while small interfering RNAs and single-stranded oligonucleotides result in transcript degradation from both cccDNA and integrated templates. These antivirals mediate their effects by reducing viral transcripts abundance, some leading to a loss of surface antigen expression, and they can potentially be added to the arsenal of drugs with demonstrable anti-HBV activity. Thus, these candidates deserve special attention for future repurposing or further development as anti-HBV therapeutics.

scholarly journals Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus

2020 ◽  
pp. 1-10
Author(s):  
Axel Pruß ◽  
Akila Chandrasekar ◽  
Jacinto Sánchez-Ibáñez ◽  
Sophie Lucas-Samuel ◽  
Ulrich Kalus ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Tissue Donors ◽  
Occult Hbv Infection ◽  
Occult Hbv ◽  
B Virus ◽  
Immunodeficiency Virus

<b><i>Background:</i></b> Although transmission of pathogenic viruses through human tissue grafts is rare, it is still one of the most serious dreaded risks of transplantation. Therefore, in addition to the detailed medical and social history, a comprehensive serologic and molecular screening of the tissue donors for relevant viral markers for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) is necessary. In the case of reactive results in particular, clear decisions regarding follow-up testing and the criteria for tissue release must be made. <b><i>Methods:</i></b> Based on the clinical relevance of the specific virus markers, the sensitivity of the serological and molecular biological methods used and the application of inactivation methods, algorithms for tissue release are suggested. <b><i>Results:</i></b> Compliance with the preanalytical requirements and assessment of a possible hemodilution are mandatory requirements before testing the blood samples. While HIV testing follows defined algorithms, the procedures for HBV and HCV diagnostics are under discussion. Screening and decisions for HBV are often not as simple, e.g., due to cases of occult HBV infection, false-positive anti-HBc results, or early window period positive HBV NAT results. In the case of HCV diagnostics, modern therapies with direct-acting antivirals, which are often associated with successful treatment of the infection, should be included in the decision. <b><i>Conclusion:</i></b> In HBV and HCV testing, a high-sensitivity virus genome test should play a central role in diagnostics, especially in the case of equivocal serology, and it should be the basis for the decision to release the tissue. The proposed test algorithms and decisions are also based on current European recommendations and standards for safety and quality assurance in tissue and cell banking.

Sign in / Sign up

Export Citation Format

Share Document